Literature DB >> 19890252

Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia.

E L Olvey1, S Clauschee, D C Malone.   

Abstract

The objective of this study was to evaluate the agreement among the US Department of Veterans Affairs (VA) listing of "critical" drug-drug interactions (DDIs) and two standard drug-interaction compendia. A list of critical DDIs, as defined by the VA, was compared with two standard commercially available compendia (Micromedex DRUG-REAX and Drug Interactions: Analysis and Management (DIAM)) in order to determine the level of agreement among the systems. Of 982 DDIs classified as critical by the VA, only 136 DDIs (13.7%) were considered critical in all three systems. Our conclusion was that, overall, there is poor agreement among the compendia and the VA system.

Mesh:

Substances:

Year:  2009        PMID: 19890252     DOI: 10.1038/clpt.2009.198

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

1.  High-priority drug-drug interactions for use in electronic health records.

Authors:  Shobha Phansalkar; Amrita A Desai; Douglas Bell; Eileen Yoshida; John Doole; Melissa Czochanski; Blackford Middleton; David W Bates
Journal:  J Am Med Inform Assoc       Date:  2012-04-26       Impact factor: 4.497

2.  A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports.

Authors:  Nicholas P Tatonetti; Guy Haskin Fernald; Russ B Altman
Journal:  J Am Med Inform Assoc       Date:  2011-06-14       Impact factor: 4.497

3.  Drug Interactions in Space: a Cause for Concern?

Authors:  Erez Berman; Sara Eyal
Journal:  Pharm Res       Date:  2019-05-31       Impact factor: 4.200

4.  Generating Evidence of Clinical Outcomes of Drug-Drug Interactions.

Authors:  Katsiaryna Bykov; Joshua J Gagne
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

5.  Definition of variables required for comprehensive description of drug dosage and clinical pharmacokinetics.

Authors:  Anna V Medem; Hanna M Seidling; Hans-Georg Eichler; Jens Kaltschmidt; Michael Metzner; Carina M Hubert; David Czock; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2017-02-14       Impact factor: 2.953

6.  Comparative evaluation of three clinical decision support systems: prospective screening for medication errors in 100 medical inpatients.

Authors:  Daniela Fritz; Alessandro Ceschi; Ivanka Curkovic; Martin Huber; Marco Egbring; Gerd A Kullak-Ublick; Stefan Russmann
Journal:  Eur J Clin Pharmacol       Date:  2012-02-29       Impact factor: 2.953

7.  Similarity-based modeling in large-scale prediction of drug-drug interactions.

Authors:  Santiago Vilar; Eugenio Uriarte; Lourdes Santana; Tal Lorberbaum; George Hripcsak; Carol Friedman; Nicholas P Tatonetti
Journal:  Nat Protoc       Date:  2014-08-14       Impact factor: 13.491

8.  Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis.

Authors:  Katsiaryna Bykov; Sebastian Schneeweiss; Robert J Glynn; Murray A Mittleman; David W Bates; Joshua J Gagne
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

9.  Toward a complete dataset of drug-drug interaction information from publicly available sources.

Authors:  Serkan Ayvaz; John Horn; Oktie Hassanzadeh; Qian Zhu; Johann Stan; Nicholas P Tatonetti; Santiago Vilar; Mathias Brochhausen; Matthias Samwald; Majid Rastegar-Mojarad; Michel Dumontier; Richard D Boyce
Journal:  J Biomed Inform       Date:  2015-04-24       Impact factor: 6.317

10.  High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.

Authors:  Rehana Jamani; Esther K Lee; Scott R Berry; Ronak Saluja; Carlo DeAngelis; Angie Giotis; Urban Emmenegger
Journal:  Eur J Clin Pharmacol       Date:  2016-08-25       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.